Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Size, Share, By Therapy Type (Autologous TIL Therapy, Allogeneic TIL Therapy), By Indication (Indication, Hematologic Malignancies), By Source of TILs (Surgical Tumor Samples, Blood Samples), and By Region - Trends, Analysis and Forecast till 2034

Tumor-Infiltrating lymphocyte (TIL) therapy market size was valued at USD 0.1 Billion in 2024 and is expected to reach USD 2.1 Billion by 2034, growing at a CAGR of 40%

TIL Therapy is a new form of adoptive cell transfer immunotherapy used to treat cancer. This is a personalized approach to treatment that uses the body's natural immunity in fighting cancer cells. It involves harvesting the T lymphocytes, a type of leukocyte that has managed to infiltrate a tumor but is now ineffective in fighting it. It all starts with the surgical removal of part of a patient's tumor. Scientists then isolate the TILs from that sample and culture and expand them in a laboratory. This can take several weeks—billions of TILs.

Meanwhile, the patient is given a lymphodepleting chemotherapy regimen to make space in the immune system for the new TILs. Once the TILs have expanded sufficiently, they are administered into the patient's circulation. Reintroduced TILs are already antigen-experienced and will recognize and attack cancer cells specifically. After infusion, patients typically receive high doses of interleukin-2, a protein that stimulates the growth and activity of T cells, further increasing the effectiveness of this therapy.

The Tumor-Infiltrating Lymphocyte Therapy market is becoming an outgrowth of the broader landscape for immunotherapies. It is based on the action of the immune system over cancer. TILs are a specific subgroup of immune cells that infiltrate and live within the tumors. They are lymphocytes with a special capacity to recognize and attack cancerous cells, therefore being potential power weapons against several malignancies.   General Concept of TIL Therapy The concept behind TIL therapy is pretty straightforward. First, it requires the tumor tissue obtained through surgery from a patient. From this tissue, TILs are harvested and then expanded in vitro for an enormous increase in the number of cells. After that, these activated immune cells are infused back into the patient, where they multiply to mount a selective attack on the cancer cells. This treatment is hopeful for advanced or metastatic cancers, either of which have become resistant to traditional treatments.   Factors that have contributed to the rapid growth of the TIL therapy market include the increased prevalence of cancer, which demands innovative treatment options, and shortcomings and side effects of conventional chemotherapy and radiation that drive interest in alternative therapies like immunotherapy. TIL therapy has had impressive clinical outcomes against certain cancer types, particularly melanoma, and is under active investigation for the treatment of other Indications. It is further supported by the development of cell culture and manufacturing technologies to create standardized products of TIL therapy. This increased the interest of pharmaceutical companies and biotech firms, resulting in considerable investments in R&D. Consequently, clinical trials for evaluating TIL therapy in different cancer indications increased.

On the other hand, despite the encouraging potential, the challenges also wall around the TIL therapy market. This calls for a complex and time-consuming manufacturing process, which comes parallel with being expensive. Moreover, while TIL therapy has been quite effective for some patients, it does not work for everyone; therefore, further predictive biomarkers research is needed to identify candidates appropriate for this therapy. The TIL therapy market will grow exponentially within the following years. One can easily foresee even more progress with TIL therapy as knowledge regarding the immune system and cancer biology increases, creating improved patient outcomes that might eventually change how cancer is treated worldwide.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Key Drivers of Target Market:

Advancements in Immunotherapy

• Major drivers are rapid progress in the field of immunotherapy and cellular therapies, particularly that of TIL therapy. Breakthroughs in understanding tumor immunology and technical advances in cell culture and expansion have added to the efficacy of TIL therapies. The increased incidences of the various types of cancers, as well as both Indications and cancers of the blood, drive the demand for new and viable treatment. TIL treatment provides hope for the patient when standard responses are not extensive.

Ever-Growing Research and Development

• The growing investments in cancer research and development, along with large funding from public and private sectors, all favor the growth of TILs-associated therapies. Back translational studies and clinical trials support the designing and development of the therapies. Innovations in genetic engineering, cell processing, and tumor profiling technologies help in the development and application process of TIL therapies. Improved methods for TIL isolation, expansion, and modification optimize outcomes from therapy and prevent harm to patients.

Restrains:

Complex Manufacturing

• The isolation, expansion, and reinfusion methodologies are considered highly complex to TILs. Variability in manufacturing and quality control, which results from extremely complex preparations of the therapy, could reduce consistency and, therefore, efficacy. Despite promising results, clinical evidence supporting TIL therapy is yet under development. Limited data in the longer run and variability in the outcomes of clinical trials may affect the broad acceptance and adoption of TIL therapies.

Opportunities:

Partnerships and Collaborations

• Pharma players, research institutes, and healthcare providers can collaborate to develop and commercialize TIL therapies. In the same way, strategic partnerships would help share resources and expertise. The increasing healthcare infrastructure and growing incidence of cancer in markets like Asia-Pacific and Latin America represent potential growth markets for businesses to expand into. Therapy development tailored to local needs and regulatory environments will help drive growth.

The market is segmented based on Therapy Type, Indication, Source, and Region.

Therapy Type Insights:

• Autologous TIL Therapy involves taking the TILs from the patient's tumor tissue. What follows is expanding the patient's TILs outside of the body and then re-introducing them into the patient. This way, it boosts a patient's immune system to identify and fight against cancerous cells. It is also highly personalized, so there is very little chance of rejection; however, this can be time-consuming and costly to prepare.
• Allogeneic TIL Therapy: While autologous TIL uses TILs from the patient's own tissue/cells, allogeneic TIL therapy uses TILs from another person. The donor's TILs are selected with respect to the recipient tumor cells as a target. Although a feasible and less time-consuming approach compared to autologous therapy, this method carries a higher risk of immune rejection and GVHD, where the donor cells could target the recipient's normal tissues.

Indication insights:

• Indication: TIL therapy targets cancers that manifest in solid masses, which include melanoma, lung cancer, and ovarian cancer. Many Indications possess resistance to therapies because of the existence of their dense structure and a suppressive tumor microenvironment. Therefore, TIL therapy aims to capture and amplify the immune reactivity against these tumors to offer a personified treatment option that could, hopefully, triumph over some of these challenges.
• Hematological malignancies include tumors arising within the blood and the bone marrow and, hence, leukemia and lymphoma. Hematologic malignancies are generally more amenable to TIL therapy than Indication, as they contain more accessible tumor cells and a less complex tumor microenvironment. In this regard, TIL therapy can be very effective because it targets the cancer cells that are either present in the blood circulation or indirectly causing bone marrow cancer.

Source insights:

• Surgical Tumor Samples: TILs can be isolated from tumors surgically removed from patients. This source usually means that the tumor or a portion of it has been removed to isolate TILs. Autosurgery-derived TIL therapy is widespread, as this source originates from a patient's tumor-infiltrating lymphocytes, which are further expanded for treatment.
• Blood Samples: TILs can alternatively be retrieved from blood samples, especially for allogeneic therapies. In addition, blood samples can be used for less invasive methods. This includes isolation for those TILs that would already have transmigrated from the tumor and found their way into the circulation. Such techniques will probably apply to patients not amenable to surgery or if a less invasive approach is desired. Blood can also be a source for further TIL research and for the development of new TIL therapies.

Regional insights:

• North America: The United States and Canada hold a significant market share for TIL therapy due to the highly advanced infrastructure for healthcare systems, substantial research and development, and a high prevalence of reported cancer cases. A few major pharmaceutical and biotech companies in these countries and robust regulatory frameworks also provide the impetus for such geographies to grow and adopt innovative therapies like TIL therapy.
• Europe: Of the various TIL therapy adoption rates in this diversified market called Europe, the European Union and other countries such as the United Kingdom, Germany, and France are taking the lead in developing the therapies and their application. Incremental investment scenarios in cancer research, inclusive and supportive regulatory environments, and stimulated research interest with close collaborative interactions between research institutions and industry players drive the market further.
• Asia-Pacific: The TIL therapy market in Asia-Pacific is growing fast because of rising cancer cases, improving healthcare infrastructure, and increasing research activities. Therapeutic modalities like TIL are adopted quickly in countries such as China, Japan, and South Korea, impelled by both national demand and international ties.
• The TIL therapy market, especially in Latin America, can grow from strength to strength. This is majorly driven by emerging cancer prevalence and rising healthcare investments. Those countries—like Brazil and Mexico—whose interests are promising in adopting advanced cancer treatment continue to witness high market growth compared to already established regions.
• Middle East and Africa: TIL therapy is gradually being adopted in the Middle East and African regions as their healthcare systems continue advancing and more cancer treatment options become available. However, relatively smaller than other regional markets, rising investments in healthcare infrastructure and cancer research are predicted to drive growth here.

Tumor-Infiltrating Lymphocyte (TIL) Therapy Market Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the target market report based on Therapy Type, Indication, Source, and Region.

Segmentation:

By Therapy Type:

• Autologous TIL Therapy
• Allogeneic TIL Therapy

By Indication:

• Solid Tumors
• Hematologic Malignancies

By Source:

• Surgical Tumor Samples
• Blood Samples

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Tumor-Infiltrating Lymphocyte (TIL) Therapy Market include Iovance Biotherapeutics, Inc., Adaptimmune Therapeutics plc, TCR2 Therapeutics Inc., Lion Biotechnologies, Inc., Kite Pharma, Inc., Bristol-Myers Squibb Company, Novartis International AG, Celgene Corporation, Juno Therapeutics, Inc., Allogene Therapeutics, Inc., Syndax Pharmaceuticals, Inc.Forty seven Inc., Zymeworks Inc., Arcellx, Inc., Immatics Biotechnologies GmbH.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

• In July 2024, the FDA approved a new TIL therapy for advanced melanoma. This represents an advance in the treatment of TIL therapy for Indication, showing the way to new alternatives for treatment in patients with metastatic melanoma.
• In June 2024, An advance in TIL expansion techniques—Researchers from one of the world's largest oncology research institutes announced a pioneering improvement for TIL expansion that increases the growth and function of TILs. This discovery is likely to enhance both the efficiency and accessibility of TIL therapies to more patients who have cancer.
• In April 2024, Biotech Cos. to Collaborate for TIL Therapy Research, Two leading biotechnology firms announced an agreement to collaborate in the search to generate data for TIL therapy. Their collaboration is set to be focused on developing the next generation of TIL therapies and combinations of treatments with other forms of immunotherapy.

• Iovance Biotherapeutics, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Adaptimmune Therapeutics plc
• TCR2 Therapeutics Inc.
• Lion Biotechnologies, Inc.
• Kite Pharma, Inc.
• Bristol-Myers Squibb Company
• Novartis International AG
• Celgene Corporation
• Juno Therapeutics, Inc.
• Allogene Therapeutics, Inc.
• Syndax Pharmaceuticals, Inc.Forty Seven Inc.
• Zymeworks Inc.
• Arcellx, Inc.
• Immatics Biotechnologies GmbH

“*” marked represents similar segmentation in other categories in the respective section.

Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Therapy Type
  • Market Snippet, By Indication
  • Market Snippet, By Source
  • Market Snippet, By Region
• Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Market Trends
• Product Launch
• Merger and Acquisitions
• Impact Analysis
• PEST Analysis
• Porter’s Analysis

Market Segmentation, By Therapy Type, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Autologous TIL Therapy
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Allogeneic TIL Therapy
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Indication, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Solid Tumors
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Hematologic Malignancies
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Source, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Surgical Tumor Samples
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Blood Samples
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Region, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (USD Bn), By Therapy Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Source, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • U.S
    • Canada
• Asia Pacific
  • Market Size and Forecast (USD Bn), By Therapy Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Source, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Europe
  • Market Size and Forecast (USD Bn), By Therapy Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Source, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • UK
    • Germany
    • France
    • Russia
    • Italy
    • Rest of Europe
• Latin America
  • Market Size and Forecast (USD Bn), By Therapy Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Source, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • Brazil
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Market Size and Forecast (USD Bn), By Therapy Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Source, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East and Africa

Competitive Landscape

• Heat Map Analysis
• Company Profiles

• Iovance Biotherapeutics, Inc.
• Adaptimmune Therapeutics plc
• TCR2 Therapeutics Inc.
• Lion Biotechnologies, Inc.
• Kite Pharma, Inc.
• Bristol-Myers Squibb Company
• Novartis International AG
• Celgene Corporation
• Juno Therapeutics, Inc.
• Allogene Therapeutics, Inc.
• Syndax Pharmaceuticals, Inc.Forty Seven Inc.
• Zymeworks Inc.
• Arcellx, Inc.
• Immatics Biotechnologies GmbH

The Last Word

• Future Impact
• About Us
• Contact